文献速递心力衰竭与心肌病

靶向环磷酸鸟苷治疗心力衰竭:JACC综述

Targeting Cyclic Guanosine Monophosphate to Treat Heart Failure: JACC Review Topic of the Week.
PubMed 文献 · J Am Coll Cardiol · 2020-01-01

该综述探讨了环磷酸鸟苷(cGMP)通路在心力衰竭治疗中的作用。降低的cGMP水平促进心衰进展,调节一氧化氮-可溶性鸟苷酸环化酶-cGMP通路的药物结果不一。沙库巴曲/缬沙坦在HFrEF中取得突破性发现,维利西呱在HFrEF的3期VICTORIA试验中阳性,但联合治疗及HFpEF中的疗效尚待明确。

要点

  • cGMP水平降低参与心衰进展,靶向该通路是治疗策略。
  • 沙库巴曲/缬沙坦通过抑制脑啡肽酶和阻断血管紧张素受体在HFrEF中获益。
  • 维利西呱在HFrEF的3期VICTORIA试验阳性,联合治疗及HFpEF疗效待验证。

核心结论

  • 靶向cGMP通路治疗心衰具有潜力,沙库巴曲/缬沙坦和维利西呱在HFrEF中显示获益,但联合治疗及HFpEF中的疗效仍需进一步研究。

研究设计与样本

  • 综述总结了调节一氧化氮-可溶性鸟苷酸环化酶-cGMP通路的药物在心力衰竭中的研究证据。

主要发现

  • 硝酸酯类、合成利钠肽及类似物评估结果不一。
  • 沙库巴曲/缬沙坦在HFrEF中取得突破性发现。
  • PDE-3或PDE-5抑制结果为阴性或中性。
  • sGC刺激剂维利西呱在HFrEF的3期VICTORIA试验中阳性。

临床怎么用

  • 沙库巴曲/缬沙坦可用于HFrEF治疗。
  • 维利西呱可用于HFrEF治疗。
  • 沙库巴曲/缬沙坦与维利西呱联合治疗HFrEF的疗效尚不明确。
  • 维利西呱在HFpEF中的疗效尚不明确。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

The significant morbidity and mortality associated with heart failure with reduced ejection fraction (HFrEF) or heart failure with preserved ejection fraction (HFpEF) justify the search for novel therapeutic agents. Reduced cyclic guanosine monophosphate levels contribute to HF progression. Among molecules modulating the nitric oxide (NO)-GMP-phosphodiesterase (PDE) pathway, the evaluation of nitrates, synthetic natriuretic peptides (NP), and NP analogs has yielded mixed results. Conversely, sacubitril/valsartan, combining NP degradation inhibition through neprilysin and angiotensin receptor blockade, has led to groundbreaking findings in HFrEF. Other strategies to increase tissue cyclic guanosine monophosphate have been attempted, such as PDE-3 or PDE-5 inhibition (with negative or neutral results), NO-independent soluble guanylate cyclase (sGC) activation, or enhancement of sGC sensitivity to endogenous NO. Following the positive results of the phase 3 VICTORIA (A Study of Vericiguat in Participants With Heart Failure With Reduced Ejection Fraction) trial on the sGC stimulator vericiguat in HFrEF, the main open questions are the efficacy of the sacubitril/valsartan-vericiguat combination in HFrEF and of vericiguat in HFpEF.

来源:J Am Coll Cardiol,查看原文。版权归原作者所有。

引用

  1. Emdin M, Aimo A, Castiglione V, et al. Targeting Cyclic Guanosine Monophosphate to Treat Heart Failure: JACC Review Topic of the Week. J Am Coll Cardiol. 2020. PMID: 33032741. doi:10.1016/j.jacc.2020.08.031

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。